

Amendments to the Claims:

Please cancel Claims 41-48, 51-53, 56-67, 69-71, 73-75, 77-87 and 90-91 without prejudice or disclaimer.

1-48. Canceled

49. (Previously presented) A pharmaceutical combined preparation comprising:

(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,
and

(b) a dopamine receptor agonist, chosen from the group consisting of pergolide, amantadine, bromocriptine, cabergoline lisuride, ropinirole and pramipexole, as a combined preparation for simultaneous, separate or sequential use for treating Parkinson Disease.

50. (Previously presented) A pharmaceutical combined preparation comprising:

(a) pipamperone in a dose ranging between 5 to 15 mg of the active ingredient,
and

(b) pergolide in a dose ranging between 0.5 and 10 mg of the active ingredient, as a combined preparation for simultaneous, separate or sequential use for treating Parkinson Disease.

51-53. (Canceled)

54. (Previously presented) A pharmaceutical combined preparation comprising:

(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,
and

(b) a levodopa associated with carbidopa, as a combined preparation for simultaneous, separate or sequential use for treating Parkinson Disease.

55. (Previously presented) A pharmaceutical combined preparation comprising:
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,
and
(b) levodopa/carbidopa and is administered in a dose ranging between 2000 mg/
200 mg and 100 mg/ 10 mg of the active ingredients,
as a combined preparation for simultaneous, separate or sequential use for treating
Parkinson Disease.

56-71. (Canceled)

72. (Previously presented) A pharmaceutical combined preparation comprising:
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,
and
(b) levodopa associated with benserazide, as a combined preparation for
simultaneous, separate or sequential use for treating Parkinson Disease.

73-91. (Canceled)

92. (Previously presented) A pharmaceutical combined preparation comprising
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,
and
(b) levodopa/carbidopa and is administered in a dose ranging between 1500 mg/
150 mg and 250 mg/ 25 mg of the active ingredients,

Applicant: Erik Buntinx
Serial No.: 10/803,793
Filed: March 18, 2004
page 4 of 14

as a combined preparation for simultaneous, separate or sequential use for treating Parkinson Disease.

93. (Previously presented) A pharmaceutical combined preparation comprising
(a) pipamperone in a dose ranging between 5 and 15 mg of the active ingredient,
and
(b) levodopa/carbidopa and is administered in a dose of 500 mg/ 50 mg of the
active ingredients, as a combined preparation for simultaneous, separate or sequential use
for treating Parkinson Disease.